Ashley Gallagher, MA

Pharmacists can build trust in buprenorphine care, handle early refill red flags, and point patients to resources to help them with substance use disorder.

New Glycemia Risk Index data shows continuous glucose monitoring cuts hypo- and hyperglycemia risk in type 1 diabetes, giving pharmacists a faster way to estimate control.

Phase 3 data show a 6-valent Lyme vaccine cuts confirmed cases by 73%, paving the way for 2026 filings and new prevention options.

Harm reduction for pharmacists can include person-first language and stigma-free naloxone counseling that keeps patients with substance use disorder safer.

New study links basal‑prandial insulin to healthier remnant cholesterol in type 2 diabetes, spotlighting hidden cardiovascular risk beyond low-density lipoprotein and A1c.

Many patients struggle with the everyday realities of staying on the medication, which can include uncomfortable adverse effects.

Lilly’s once-weekly retatrutide lowers A1C up to 2% and drives nearly 17% weight loss in type 2 diabetes, signaling a powerful triple-agonist shift.

The SUPPORT Act 2025 lets pharmacists prescribe buprenorphine for opioid use disorder, but DEA training and state rules shape access and new formulations.

Mississippi pharmacies strengthen prenatal care with monthly check-ins, vitamins, aspirin, screenings, and community support for high-risk moms.

Across the United States, trafficking also takes the form of labor exploitation in farms, factories, and remote industrial regions.

MAHA-driven HHS shifts vaccines and nutrition, fueling public health debate as pharmacists battle social media misinformation and rebuild trust.

The FDA clears the highest-dose weekly semaglutide for obesity, showing 20.7% mean weight loss with the same blood sugar-lowering effects.

Pharmacists spot subtle abuse and sexual health red flags, avoid profiling, and respond safely with resources while protecting HIPAA privacy.

Pharmacists help women with type 1 diabetes plan pregnancy, adjust insulin and tech, and stay safe postpartum with personalized guidance.

MiniMed Flex is a smaller, screenless, and phone-controlled insulin automation that shows how pharmacists boost AID success for patients with diabetes.

The new parameter combines waist circumference, hypertension status, and glycated hemoglobin to determine insulin resistance.

FDA approves icotrokinra as a first-line systemic treatment of plaque psoriasis with a targeted oral peptide for adults and pediatric patients.

Many states are pushing pharmacies to move beyond the traditional dispensing role into more robust clinical care.

Combined with nutritional interventions, semaglutide also demonstrates greater weight loss compared with dulaglutide.

From proposed transparency rules to Medicare price negotiation programs, the stakes are high for pharmacy reimbursement and the sustainability of independent practices.

The FDA clears secukinumab for patients 12 years and older with tough hidradenitis suppurativa, offering weight-based IL‑17A biologic relief and new guidance on screening and safety.

Remote hub model in New Zealand upskills pharmacists to launch automated insulin delivery faster, expanding equitable access for type 1 diabetes.

This landmark decision follows previous approvals for adults 60 years and older, as well as those aged 50 to 59 years at increased risk.

Eli Lilly flags unknown impurities in compounded tirzepatide with B12 as FDA targets misleading GLP-1 marketing.

FDA approves Wellcovorin for rare FOLR1 cerebral folate deficiency, spotlighting real-world evidence, dosing goals, and key drug-interaction risks.

A study finds prior-authorization bans do not boost buprenorphine retention for patients on private insurance.

Mark Cuban Cost Plus Drug Company challenges pharmacy benefit managers' opacity, expands affordable drug access, and supports community pharmacies.

Clinical pharmacists boost A1c control and eye and foot screening for Spanish-speaking adults with diabetes, revealing why culturally fluent care matters.